Chimerix Inc (CMRX)

$0.9607

-0.03

(-2.96%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Chimerix Inc

  • Decreasing Revenue

    Revenue is down for the last 6 quarters, 32.55M → 4.0K (in $), with an average decrease of 75.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -23.98M → -18.16M (in $), with an average increase of 32.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 67.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 248.2% return, outperforming this stock by 336.6%

Performance

  • $0.95
    $1.02
    $0.96
    downward going graph

    1.04%

    Downside

    Day's Volatility :6.86%

    Upside

    5.88%

    downward going graph
  • $0.88
    $1.57
    $0.96
    downward going graph

    8.33%

    Downside

    52 Weeks Volatility :43.95%

    Upside

    38.85%

    downward going graph

Returns

PeriodChimerix IncSector (Health Care)Index (Russel 2000)
3 Months
1.13%
-1.1%
0.0%
6 Months
-4.88%
6.7%
0.0%
1 Year
-22.52%
3.2%
-0.7%
3 Years
-88.44%
15.2%
-21.6%

Highlights

Market Capitalization
89.1M
Book Value
$2.17
Earnings Per Share (EPS)
-0.93
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-520250.0%
Return On Assets TTM
-23.64%
Return On Equity TTM
-36.5%
Revenue TTM
324.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-99.5%
Gross Profit TTM
-36.5M
EBITDA
-93.0M
Diluted Eps TTM
-0.93
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.85
EPS Estimate Next Year
-0.96
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Chimerix Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 628.64%

Current $0.96
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
7.2M
↑ 60.57%
Net Income
-69.5M
↓ 2.13%
Net Profit Margin
-962.78%
↑ 616.75%
FY19Y/Y Change
Revenue
12.5M
↑ 73.49%
Net Income
-173.7M
↑ 149.95%
Net Profit Margin
-1.4K%
↓ 424.31%
FY20Y/Y Change
Revenue
5.4M
↓ 57.09%
Net Income
-42.1M
↓ 75.74%
Net Profit Margin
-784.18%
↑ 602.91%
FY21Y/Y Change
Revenue
2.0M
↓ 63.16%
Net Income
-255.8M
↑ 507.21%
Net Profit Margin
-12.9K%
↓ 12141.29%
FY22Y/Y Change
Revenue
33.8M
↑ 1609.15%
Net Income
172.2M
↓ 167.31%
Net Profit Margin
509.01%
↑ 13434.48%
FY23Y/Y Change
Revenue
324.0K
↓ 99.04%
Net Income
-82.1M
↓ 147.68%
Net Profit Margin
-25.3K%
↓ 25846.97%
Q3 FY22Q/Q Change
Revenue
32.6M
↑ 7298.86%
Net Income
241.4M
↓ 1127.55%
Net Profit Margin
741.4%
↑ 6079.81%
Q4 FY22Q/Q Change
Revenue
814.0K
↓ 97.5%
Net Income
-21.0M
↓ 108.68%
Net Profit Margin
-2.6K%
↓ 3316.34%
Q1 FY23Q/Q Change
Revenue
283.0K
↓ 65.23%
Net Income
-18.5M
↓ 11.61%
Net Profit Margin
-6.5K%
↓ 3971.35%
Q2 FY23Q/Q Change
Revenue
26.0K
↓ 90.81%
Net Income
-18.6M
↑ 0.27%
Net Profit Margin
-71.4K%
↓ 64899.86%
Q3 FY23Q/Q Change
Revenue
11.0K
↓ 57.69%
Net Income
-24.0M
↑ 29.12%
Net Profit Margin
-218.1K%
↓ 146608.4%
Q4 FY23Q/Q Change
Revenue
4.0K
↓ 63.64%
Net Income
-18.2M
↓ 24.28%
Net Profit Margin
-454.0K%
↓ 235970.45%
FY18Y/Y Change
Total Assets
190.7M
↓ 18.92%
Total Liabilities
13.1M
↓ 2.31%
FY19Y/Y Change
Total Assets
119.4M
↓ 37.41%
Total Liabilities
9.4M
↓ 28.12%
FY20Y/Y Change
Total Assets
84.7M
↓ 29.03%
Total Liabilities
11.3M
↑ 20.41%
FY21Y/Y Change
Total Assets
100.5M
↑ 18.67%
Total Liabilities
32.3M
↑ 184.55%
FY22Y/Y Change
Total Assets
279.3M
↑ 177.84%
Total Liabilities
22.5M
↓ 30.36%
FY23Y/Y Change
Total Assets
212.8M
↓ 23.83%
Total Liabilities
19.7M
↓ 12.18%
Q3 FY22Q/Q Change
Total Assets
293.9M
↑ 448.66%
Total Liabilities
19.9M
↓ 22.26%
Q4 FY22Q/Q Change
Total Assets
279.3M
↓ 4.95%
Total Liabilities
22.5M
↑ 12.83%
Q1 FY23Q/Q Change
Total Assets
258.5M
↓ 7.45%
Total Liabilities
18.2M
↓ 18.96%
Q2 FY23Q/Q Change
Total Assets
241.1M
↓ 6.75%
Total Liabilities
17.0M
↓ 6.85%
Q3 FY23Q/Q Change
Total Assets
225.3M
↓ 6.55%
Total Liabilities
17.0M
↑ 0.04%
Q4 FY23Q/Q Change
Total Assets
212.8M
↓ 5.55%
Total Liabilities
19.7M
↑ 16.29%
FY18Y/Y Change
Operating Cash Flow
-53.7M
↑ 7.18%
Investing Cash Flow
105.1M
↑ 539.61%
Financing Cash Flow
11.2M
↑ 1336.2%
FY19Y/Y Change
Operating Cash Flow
-75.2M
↑ 39.94%
Investing Cash Flow
10.6M
↓ 89.88%
Financing Cash Flow
345.0K
↓ 96.92%
FY20Y/Y Change
Operating Cash Flow
-36.0M
↓ 52.07%
Investing Cash Flow
64.7M
↑ 508.72%
Financing Cash Flow
1.4M
↑ 309.57%
FY21Y/Y Change
Operating Cash Flow
-99.9M
↑ 177.29%
Investing Cash Flow
-44.1M
↓ 168.13%
Financing Cash Flow
112.4M
↑ 7856.76%
FY22Y/Y Change
Operating Cash Flow
-46.9M
↓ 53.1%
Investing Cash Flow
70.0M
↓ 258.85%
Financing Cash Flow
-12.7M
↓ 111.32%
Q3 FY22Q/Q Change
Operating Cash Flow
7.1M
↓ 167.5%
Investing Cash Flow
238.3M
↑ 3456.25%
Financing Cash Flow
778.0K
↓ 7172.73%
Q4 FY22Q/Q Change
Operating Cash Flow
-20.0M
↓ 380.42%
Investing Cash Flow
-228.4M
↓ 195.86%
Financing Cash Flow
-32.0K
↓ 104.11%
Q1 FY23Q/Q Change
Operating Cash Flow
-22.2M
↑ 11.19%
Investing Cash Flow
12.1M
↓ 105.31%
Financing Cash Flow
199.0K
↓ 721.87%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.3M
↓ 35.47%
Investing Cash Flow
18.5M
↑ 52.62%
Financing Cash Flow
-31.0K
↓ 115.58%

Technicals Summary

Sell

Neutral

Buy

Chimerix Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Chimerix Inc
Chimerix Inc
-16.46%
-4.88%
-22.52%
-88.44%
-63.61%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.73%
6.03%
21.0%
79.35%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Chimerix Inc
Chimerix Inc
0.48
NA
0.0
-0.85
-0.36
-0.24
NA
2.17
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Chimerix Inc
Chimerix Inc
Buy
$89.1M
-63.61%
0.48
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • RA Capital Management, LLC

    9.86%
  • Monaco Asset Management

    4.91%
  • Vanguard Group Inc

    4.87%
  • Armistice Capital, LLC

    2.91%
  • Citadel Advisors Llc

    2.72%
  • Goldman Sachs Group Inc

    2.64%

Company Information

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

Organization
Chimerix Inc
Employees
72
CEO
Mr. Michael T. Andriole M.B.A.
Industry
Health Technology

FAQs